<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://latebreakingscience.com/wp-content/plugins/seriously-simple-podcasting/templates/feed-stylesheet.xsl?v=2"?><rss version="2.0"
	 xmlns:content="http://purl.org/rss/1.0/modules/content/"
	 xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	 xmlns:dc="http://purl.org/dc/elements/1.1/"
	 xmlns:atom="http://www.w3.org/2005/Atom"
	 xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	 xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	 xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd"
	 xmlns:googleplay="http://www.google.com/schemas/play-podcasts/1.0"
	 xmlns:podcast="https://podcastindex.org/namespace/1.0"
	 xmlns:ssp="https://castos.com/seriously-simple-podcasting/namespace/1.0"
	>
		<channel>
		<title>ASCO 2022</title>
		<atom:link href="https://latebreakingscience.com/feed/podcast/asco-2022/" rel="self" type="application/rss+xml"/>
		<link>https://latebreakingscience.com/series/asco-2022/</link>
		<description></description>
		<lastBuildDate>Thu, 20 Nov 2025 14:00:44 +0000</lastBuildDate>
		<language>en-US</language>
		<copyright>&#xA9; 2026 Late Breaking Science</copyright>
		<itunes:subtitle></itunes:subtitle>
		<itunes:author>Late Breaking Science</itunes:author>
		<itunes:summary></itunes:summary>
		<itunes:owner>
			<itunes:name>Late Breaking Science</itunes:name>
		</itunes:owner>
		<itunes:explicit>false</itunes:explicit>
		<itunes:image href="https://latebreakingscience.com/wp-content/uploads/2019/02/Late_Breaking_Science_cover-video-capsules.svg"></itunes:image>
			<image>
				<url>https://latebreakingscience.com/wp-content/uploads/2019/02/Late_Breaking_Science_cover-video-capsules.svg</url>
				<title>ASCO 2022</title>
				<link>https://latebreakingscience.com/series/asco-2022/</link>
			</image>
		<googleplay:author><![CDATA[Late Breaking Science]]></googleplay:author>
						<googleplay:description></googleplay:description>
			<googleplay:explicit>No</googleplay:explicit>
			<googleplay:image href="https://latebreakingscience.com/wp-content/uploads/2019/02/Late_Breaking_Science_cover-video-capsules.svg"></googleplay:image>
			<podcast:locked>yes</podcast:locked>
		<podcast:guid>c3a124f4-50af-5996-a7a4-d51c71a2c16c</podcast:guid>
		
		<!-- podcast_generator="SSP by Castos/3.16.3" Seriously Simple Podcasting plugin for WordPress (https://wordpress.org/plugins/seriously-simple-podcasting/) -->
		<generator>https://wordpress.org/?v=7.0.4</generator>

<item>
	<title>Dr. Paul Wheatley-Price</title>
	<link>https://latebreakingscience.com/podcast/dr-wheatley-price-asco-2022/</link>
	<pubDate>Tue, 21 Jun 2022 19:29:44 +0000</pubDate>
	<dc:creator><![CDATA[Late Breaking Science]]></dc:creator>
	<guid isPermaLink="false">http://latebreakingscience.com/?post_type=podcast&#038;p=891</guid>
	<description><![CDATA[Abstract 9024, poster 12 – Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer. Abstract 3099, poster 91 – Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors.]]></description>
	<itunes:subtitle><![CDATA[Abstract 9024, poster 12 – Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer. Abstract 3099, poster 91 – Updated analysis of the efficacy and safety of entrectinib in patients (pts) with lo]]></itunes:subtitle>
	<content:encoded><![CDATA[Abstract 9024, poster 12 – Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer. Abstract 3099, poster 91 – Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors.]]></content:encoded>
	<enclosure url="https://latebreakingscience.com/podcast-download/891/dr-wheatley-price-asco-2022.mp3" length="22754605" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Abstract 9024, poster 12 – Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer. Abstract 3099, poster 91 – Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>11:51</itunes:duration>
	<itunes:author><![CDATA[Late Breaking Science]]></itunes:author>	<googleplay:description><![CDATA[Abstract 9024, poster 12 – Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer. Abstract 3099, poster 91 – Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors.]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Dr. Stephanie Snow</title>
	<link>https://latebreakingscience.com/podcast/dr-snow-asco-2022/</link>
	<pubDate>Tue, 21 Jun 2022 19:26:46 +0000</pubDate>
	<dc:creator><![CDATA[Late Breaking Science]]></dc:creator>
	<guid isPermaLink="false">http://latebreakingscience.com/?post_type=podcast&#038;p=890</guid>
	<description><![CDATA[Abstract 3006 – CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions.]]></description>
	<itunes:subtitle><![CDATA[Abstract 3006 – CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions.]]></itunes:subtitle>
	<content:encoded><![CDATA[Abstract 3006 – CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions.]]></content:encoded>
	<enclosure url="https://latebreakingscience.com/podcast-download/890/dr-snow-asco-2022.mp3" length="15925152" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Abstract 3006 – CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>8:18</itunes:duration>
	<itunes:author><![CDATA[Late Breaking Science]]></itunes:author>	<googleplay:description><![CDATA[Abstract 3006 – CRESTONE: Initial efficacy and safety of seribantumab in solid tumors harboring NRG1 fusions.]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Dr. Cheryl Ho</title>
	<link>https://latebreakingscience.com/podcast/dr-ho-asco-2022/</link>
	<pubDate>Tue, 21 Jun 2022 19:26:14 +0000</pubDate>
	<dc:creator><![CDATA[Late Breaking Science]]></dc:creator>
	<guid isPermaLink="false">http://latebreakingscience.com/?post_type=podcast&#038;p=889</guid>
	<description><![CDATA[Abstract 9007 – Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20).]]></description>
	<itunes:subtitle><![CDATA[Abstract 9007 – Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20).]]></itunes:subtitle>
	<content:encoded><![CDATA[Abstract 9007 – Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20).]]></content:encoded>
	<enclosure url="https://latebreakingscience.com/podcast-download/889/dr-ho-asco-2022.mp3" length="15453694" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Abstract 9007 – Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20).]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>8:03</itunes:duration>
	<itunes:author><![CDATA[Late Breaking Science]]></itunes:author>	<googleplay:description><![CDATA[Abstract 9007 – Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20).]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Dr. Quincy Chu</title>
	<link>https://latebreakingscience.com/podcast/dr-chu-asco-2022/</link>
	<pubDate>Tue, 21 Jun 2022 19:25:46 +0000</pubDate>
	<dc:creator><![CDATA[Late Breaking Science]]></dc:creator>
	<guid isPermaLink="false">http://latebreakingscience.com/?post_type=podcast&#038;p=888</guid>
	<description><![CDATA[Abstract TPS9137, poster 123a – Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non–small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04).]]></description>
	<itunes:subtitle><![CDATA[Abstract TPS9137, poster 123a – Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non–small cell lung cancer (NSCLC) harbori]]></itunes:subtitle>
	<content:encoded><![CDATA[Abstract TPS9137, poster 123a – Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non–small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04).]]></content:encoded>
	<enclosure url="https://latebreakingscience.com/podcast-download/888/dr-chu-asco-2022.mp3" length="12906651" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Abstract TPS9137, poster 123a – Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non–small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04).]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>6:43</itunes:duration>
	<itunes:author><![CDATA[Late Breaking Science]]></itunes:author>	<googleplay:description><![CDATA[Abstract TPS9137, poster 123a – Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non–small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04).]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>

<item>
	<title>Dr. Normand Blais</title>
	<link>https://latebreakingscience.com/podcast/dr-blais-asco-2022/</link>
	<pubDate>Tue, 21 Jun 2022 19:25:14 +0000</pubDate>
	<dc:creator><![CDATA[Late Breaking Science]]></dc:creator>
	<guid isPermaLink="false">http://latebreakingscience.com/?post_type=podcast&#038;p=882</guid>
	<description><![CDATA[Abstract 9008 – Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.]]></description>
	<itunes:subtitle><![CDATA[Abstract 9008 – Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.]]></itunes:subtitle>
	<content:encoded><![CDATA[Abstract 9008 – Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.]]></content:encoded>
	<enclosure url="https://latebreakingscience.com/podcast-download/882/dr-blais-asco-2022.mp3" length="20680692" type="audio/mpeg"></enclosure>
	<itunes:summary><![CDATA[Abstract 9008 – Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.]]></itunes:summary>
	<itunes:explicit>false</itunes:explicit>
	<itunes:block>no</itunes:block>
	<itunes:duration>10:46</itunes:duration>
	<itunes:author><![CDATA[Late Breaking Science]]></itunes:author>	<googleplay:description><![CDATA[Abstract 9008 – Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study.]]></googleplay:description>
	<googleplay:explicit>No</googleplay:explicit>
	<googleplay:block>no</googleplay:block>
</item>
	</channel>
</rss>
